These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The use of monoclonal antibody (rituximab) in the treatment of type II mixed cryoglobulinemia. Rego TC; Massumoto CM; Batista RS; Moura LH; Soares LM; Gomes AP Braz J Infect Dis; 2007 Feb; 11(1):174-5. PubMed ID: 17625752 [TBL] [Abstract][Full Text] [Related]
24. Serological markers of autoimmunity in renal transplant patients with chronic hepatitis C. Rostaing L; Modesto A; Cisterne JM; Izopet J; Oksman F; Duffaut M; Abbal M; Durand D Am J Nephrol; 1998; 18(1):50-6. PubMed ID: 9481439 [TBL] [Abstract][Full Text] [Related]
25. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Saadoun D; Resche-Rigon M; Sene D; Perard L; Karras A; Cacoub P Ann Rheum Dis; 2008 Oct; 67(10):1431-6. PubMed ID: 18178690 [TBL] [Abstract][Full Text] [Related]
26. [Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjögren's disease: preliminary data]. Logvinenko OA; Vasil'ev VI; Sedyshev SKh; Safonova TN; Rodionova EB; Kokosadze NV; Aleksandrova EN; Cherkasova MV; Radenska-Lopovok SG; Nasonov EL Ter Arkh; 2012; 84(12):88-96. PubMed ID: 23479998 [TBL] [Abstract][Full Text] [Related]
27. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Quartuccio L; Soardo G; Romano G; Zaja F; Scott CA; De Marchi G; Fabris M; Ferraccioli G; De Vita S Rheumatology (Oxford); 2006 Jul; 45(7):842-6. PubMed ID: 16418196 [TBL] [Abstract][Full Text] [Related]
28. Long-term remission with rituximab in a patient with severe hepatitis C virus-induced mixed cryoglobulinemia. Fortea-Ormaechea JI; Lozano-Maya M; Adán-Merino L; Barrio-Antoranz J; Martín-Chavarri S; Corchete-Prats E; Martínez-Acebes E; Aldeguer-Martínez M Rev Esp Enferm Dig; 2013 Sep; 105(8):490-3. PubMed ID: 24274448 [TBL] [Abstract][Full Text] [Related]
29. Rituximab in highly sensitized kidney transplant recipients. Munoz AS; Rioveros AA; Cabanayan-Casasola CB; Danguilan RA; Ona ET Transplant Proc; 2008 Sep; 40(7):2218-21. PubMed ID: 18790197 [TBL] [Abstract][Full Text] [Related]
30. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report. Massari M; Catania A; Magnani G Dig Liver Dis; 2007 Sep; 39 Suppl 1():S134-5. PubMed ID: 17936216 [No Abstract] [Full Text] [Related]
32. Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia. Korte MR; van Heerde MJ; de Man RA; Betjes MH Neth J Med; 2008 Jan; 66(1):27-30. PubMed ID: 18219065 [TBL] [Abstract][Full Text] [Related]
33. [Renal involvement of cryoglobulinemia]. Karras A Nephrol Ther; 2018 Apr; 14(2):118-126. PubMed ID: 29545130 [TBL] [Abstract][Full Text] [Related]
34. Cryoglobulinaemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab. Braun A; Neumann T; Oelzner P; Hein G; Gröne HJ; Ziemer M; Wolf G Rheumatol Int; 2008 Mar; 28(5):503-6. PubMed ID: 17924113 [TBL] [Abstract][Full Text] [Related]
35. Critical evaluation of rituximab rescue in 27 patients with different types of kidney disease. Ganzemueller J; Hartmann B; Keller F; Stracke S Minerva Urol Nefrol; 2011 Dec; 63(4):263-72. PubMed ID: 21996981 [TBL] [Abstract][Full Text] [Related]
36. Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature. Wink F; Houtman PM; Jansen TL Clin Rheumatol; 2011 Feb; 30(2):293-300. PubMed ID: 21053035 [TBL] [Abstract][Full Text] [Related]
37. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Saadoun D; Rosenzwajg M; Landau D; Piette JC; Klatzmann D; Cacoub P Blood; 2008 Jun; 111(11):5334-41. PubMed ID: 18292291 [TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Petrarca A; Rigacci L; Caini P; Colagrande S; Romagnoli P; Vizzutti F; Arena U; Giannini C; Monti M; Montalto P; Matucci-Cerinic M; Bosi A; Laffi G; Zignego AL Blood; 2010 Jul; 116(3):335-42. PubMed ID: 20308604 [TBL] [Abstract][Full Text] [Related]
39. B cell homeostasis in chronic hepatitis C virus-related mixed cryoglobulinemia is maintained through naïve B cell apoptosis. Holz LE; Yoon JC; Raghuraman S; Moir S; Sneller MC; Rehermann B Hepatology; 2012 Nov; 56(5):1602-10. PubMed ID: 22556016 [TBL] [Abstract][Full Text] [Related]
40. Rituximab treatment for a patient with type I cryoglobulinemic glomerulonephritis. Pandrangi S; Singh A; Wheeler DE; Rossi NF Nat Clin Pract Nephrol; 2008 Jul; 4(7):393-7. PubMed ID: 18493239 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]